NEW YORK (GenomeWeb News) – Bruker said today that a member of the Laukien family sold two million of the company's shares in a block trade, and that CEO Frank Laukien bought 100,000 shares from the same family member in a private transaction.

The life science and environmental research tools maker, which now has a public float of 50.9 million shares, said that the unidentified Laukien family member is not involved in the company's business. The aggregate number of shares sold yesterday amounts to 12.6 percent of the selling shareholder's ownership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."